Cargando…

Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil

BACKGROUND: The objective was to identify separate cognitive domains in the standard assessment tools (MMSE, ADAS-Cog) and analyze the process of decline within domains during three years in Alzheimer's disease (AD) patients with donepezil treatment. METHOD: AD patients (n = 421) were recruited...

Descripción completa

Detalles Bibliográficos
Autores principales:	Persson, Cecilia M, Wallin, Åsa K, Levander, Sten, Minthon, Lennart
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2666627/ https://www.ncbi.nlm.nih.gov/pubmed/19208247 http://dx.doi.org/10.1186/1471-2377-9-7

Ejemplares similares

Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy
por: Wattmo, Carina, et al.
Publicado: (2016)

Predictors of long-term cognitive outcome in Alzheimer's disease
por: Wattmo, Carina, et al.
Publicado: (2011)

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
por: Wattmo, Carina, et al.
Publicado: (2012)

Progression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategies
por: Wattmo, Carina, et al.
Publicado: (2013)

Galantamine treatment in Alzheimer’s disease: response and long-term outcome in a routine clinical setting
por: Wallin, Åsa K, et al.
Publicado: (2011)

Solitary living in Alzheimer’s disease over 3 years: association between cognitive and functional impairment and community-based services
por: Wattmo, Carina, et al.
Publicado: (2014)

Transdermal donepezil on the treatment of Alzheimer’s disease
por: Sozio, Piera, et al.
Publicado: (2012)

The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial
por: Rockwood, Kenneth, et al.
Publicado: (2007)

Early- versus late-onset Alzheimer’s disease in clinical practice: cognitive and global outcomes over 3 years
por: Wattmo, Carina, et al.
Publicado: (2017)

A Network Pharmacology Based Research on the Mechanism of Donepezil in Treating Alzheimer's Disease
por: Liu, Lihua, et al.
Publicado: (2022)

Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases
por: Pooladgar, Parham, et al.
Publicado: (2022)

Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer’s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study
por: Palmqvist, Sebastian, et al.
Publicado: (2012)

Antibody Heavy Chain Variable Domains of Different Germline Gene Origins Diversify through Different Paths
por: Kirik, Ufuk, et al.
Publicado: (2017)

Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil
por: Hwang, Tae-Young, et al.
Publicado: (2016)

Use of Methylphenidate in Excessive Daytime Sleepiness in Alzheimer’s Patients Treated with Donepezil: Case Series
por: Bidzan, Leszek, et al.
Publicado: (2020)

A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2010)

Cognitive Results of CANTAB Tests and Their Change Due to the First Dose of Donepezil May Predict Treatment Efficacy in Alzheimer Disease
por: Kuzmickienė, Jurgita, et al.
Publicado: (2015)

Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases
por: Alvarez, X. Anton, et al.
Publicado: (2016)

Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics
por: Cacabelos, Ramón
Publicado: (2007)

Donepezil enhances understanding of degraded speech in Alzheimer's disease
por: Hardy, Chris J. D., et al.
Publicado: (2017)

Donepezil Treatment for Alzheimer's Disease in Chronic Dialysis Patients
por: Yiannopoulou, Konstantina G., et al.
Publicado: (2019)

Cerebellar Cognitive Affective Syndrome Improved by Donepezil
por: Nishida, Yoichiro, et al.
Publicado: (2018)

Donepezil for mild cognitive impairment in Parkinson’s disease
por: Baik, Kyoungwon, et al.
Publicado: (2021)

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
por: Hertze, Joakim, et al.
Publicado: (2014)

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2014)

CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease
por: Westin, Karin, et al.
Publicado: (2012)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Effects of donepezil on cognitive functions and the expression level of β-amyloid in peripheral blood of patients with Alzheimer's disease
por: Ma, Yunxia, et al.
Publicado: (2018)

Studies on Interaction of Buffalo Brain Cystatin with Donepezil: An Alzheimer's Drug
por: Amin, Fakhra, et al.
Publicado: (2013)

Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease
por: Unzeta, Mercedes, et al.
Publicado: (2016)

Effect of donepezil on transcranial magnetic stimulation parameters in Alzheimer's disease
por: Hwang, Yun Tae, et al.
Publicado: (2018)

Commentary: Donepezil enhances understanding of degraded speech in Alzheimer's disease
por: Campbell, Tom A., et al.
Publicado: (2018)

Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer’s Disease
por: Chase, Thomas N., et al.
Publicado: (2017)

No Diagnostic Value of Plasma Clusterin in Alzheimer's Disease
por: Silajdžić, Edina, et al.
Publicado: (2012)

Effect of Resveratrol Combined with Donepezil Hydrochloride on Inflammatory Factor Level and Cognitive Function Level of Patients with Alzheimer's Disease
por: Fang, Xincui, et al.
Publicado: (2022)

Short-Term Response to Cholinesterase Inhibitors in Alzheimer’s Disease Delays Time to Nursing Home Placement
por: Wattmo, Carina, et al.
Publicado: (2018)

A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease
por: Andersson, Carl-Henrik, et al.
Publicado: (2016)

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
por: Farlow, Martin, et al.
Publicado: (2011)

Clinical efficacy and safety of donepezil in the treatment of Alzheimer’s disease in Chinese patients
por: Zhang, Nan, et al.
Publicado: (2018)

Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer’s disease therapy
por: Pachón-Angona, Irene, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nofn115tu94lnfgqque3saqtc5